Eating for RA The majority of practicing rheums at RheumNow Live were unaware of the new ACR guidelines issued in 2022 regarding dietary and lifestyle recommendations for patients with RA. Dr. Monica Guma reviewed these guidelines during her lecture. https://t.co/9herN2musx https://t.co/P1xJn2lDrg

Serial plasma samples assayed for 92 inflammation-related proteins, during and after gout attacks. 21 were differentially expressed. Gout flares assoc w/ increased IL-6, CSF-1, VEGF-A & tumour necrosis factor superfamily 14 (TNFSF14 was highest) https://t.co/2p8vTFcmvD https://t.co/5z1gYdsKJO

Week 52 outcomes of 180 lupus nephritis pts (IV, VI, III) from AMP academic centers (rx w/ standard of care) showed 22% complete resp,  22% partial resp, 42% non-responder& 14% undetermined. 8/180 (4.4%) had CR sustained Wk 12 to 52; 10% PR. An unmet need! https://t.co/MJklf0Xhih https://t.co/w6a1fLKmoF

Cochrane Review: How Good is Ultrasound Diagnosing GCA? Is temporal artery ultrasound (US) equivalent or superior to the reference standard of temporal artery biopsy (TAB) when diagnosing giant cell arteritis (GCA)? https://t.co/AcETp0TJBF https://t.co/eKVmaro7D0

Vasculitis Pearls Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks https://t.co/Oee5nRhTAx https://t.co/sJGwCzLUQq

How do you manage enthesitis? Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). https://t.co/BlC3onBYSX https://t.co/OXPdZuJHaN

Long-Term, open-label study enrolled EGPA (MIRRA study) required prednisolone ≥5 mg/d, pts cont mepolizumab 300 mg Sc q 4 wks +SOC. 100 pts - 71% completed, 3% d/C due to AEs. Exposure~38 mos; 38% serious AEs (30/100PYs) (worsening of asthma, EGPA https://t.co/GKxXN8p2Wz https://t.co/TFd9s3tfjK

Top 5 Clinical Pearls in RA Management #RNL2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in RA." https://t.co/DUalEZbfJB https://t.co/RZsW0SKc4J

Five Takeaways in PsA/SpA at RNL 2024 Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Click the link to read our five key takeaways and clinical pearls. https://t.co/ekKUl5WelF https://t.co/IdPXd7LR65

The ARIAA trial tested the utility of IV abatacept in individuals ACPA+ arthralgia patients with subclinical inflammation and showed abatacept to decrease MRI inflammation, clinical symptoms, and risk of future RA development. https://t.co/PdYLKwT0z9 https://t.co/O8uHxzleIK

Gabapentinoid use in COPD pts assoc w/ signif increased risk of severe exacerbation. Compared with nonuse, GABA use incr risk of COPD exacerbation when used for epilepsy (HR 1.58), neuropathic pain (HR 1.35), chronic pain (HR 1.49) https://t.co/EyONh9sASh https://t.co/Sr2FyJQzBj

Immune-Related Adverse Events of Immune Checkpoint Inhibitors - FULL READ overview in Annals of Internal Medicine. irAEs occur from few days to 1 year after ICI initiation; w/ 3-fold higher risk 1st 4 wks & only 7% starting 1 year after ICI https://t.co/jxEAl3rlCd https://t.co/IlmvV5kNfP